This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.
Mitragyna speciosa
This herb is NOT recommended during pregnancy due to potential risks to the developing fetus.
This herb is NOT recommended while breastfeeding as effects on infants are unknown.
Consult your healthcare provider before use.
A Southeast Asian tree whose leaves have dose-dependent stimulant and opioid-like effects. Controversial and regulated.
A Southeast Asian tree whose leaves have dose-dependent stimulant and opioid-like effects. Controversial and regulated. Key active compounds include Mitragynine, 7-hydroxymitragynine, Speciociliatine.
Mitragynine, along with 7-hydroxymitragynine and Speciociliatine, are the primary bioactive compounds in Kratom. These compounds acts on pain pathways via anti-inflammatory and neuroactive effects.
Opioid receptor activity
Limited clinical evidence; primarily supported by traditional use and preliminary studies
Pain management research
Limited clinical evidence; primarily supported by traditional use and preliminary studies
Addiction withdrawal studies
Pain relief
Based on traditional use; clinical evidence limited
Energy at low doses
Based on traditional use; clinical evidence limited
Opium withdrawal aid
Based on traditional use; clinical evidence limited
Found an error or have a correction for Kratom?
Report an Issue →